EASTONBIOPHARMACEUTICALS(SH:688513) Sou Hu Cai Jing·2025-07-29 05:42Group 1 - The core viewpoint highlights the strong performance and liquidity of the Science and Technology Innovation Pharmaceutical ETF managed by Harvest, which has seen significant trading activity and growth in both scale and shares [2] - As of July 28, the ETF recorded a turnover rate of 22.91% and a transaction volume of 48.1073 million yuan, indicating active market participation [2] - The ETF's net asset value increased by 54.52% over the past year, ranking it in the top 12.25% among comparable index equity funds [2] Group 2 - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 50.3% of the index, with leading companies including United Imaging Healthcare and BeiGene [2] - Recent collaboration between Hengrui Medicine and GlaxoSmithKline (GSK) involves the joint development of up to 12 innovative drugs, with GSK making an initial payment of 500 million USD and potential milestone payments totaling around 12 billion USD [4] - The pharmaceutical industry is experiencing high growth, with recommendations for companies in Pharma and Biopharma/Biotech sectors as they enter a phase of performance expansion [5]